Advertisement

ADVERTISEMENT

Lung Cancer

Dr Jazieh Highlights the Prevalence of ALK+ NSCLC in the Middle East and North Africa
Podcasts
Dr Jazieh Highlights the Prevalence of ALK+ NSCLC in the Middle East and North Africa
09/28/2020
Abdul Rahman Jazieh, MD, MPH, discusses a study on the prevalence of ALK+ NSCLC in the Middle East and North Africa and the importance of testing, presented at the ESMO 2020 Virtual Congress.
Abdul Rahman Jazieh, MD, MPH, discusses a study on the prevalence of ALK+ NSCLC in the Middle East and North Africa and the importance of testing, presented at the ESMO 2020 Virtual Congress.
Abdul Rahman Jazieh, MD, MPH,...
09/28/2020
Oncology
Durvalumab Shows Promise in Phase 2 Trial of Patients With Pleural Mesothelioma
Videos
Durvalumab Shows Promise in Phase 2 Trial of Patients With Pleural Mesothelioma
06/30/2020
Claire Verschraegen, MD, comments on a phase 2 study examining the use of chemotherapy with durvalumab in patients with pleural mesothelioma.
Claire Verschraegen, MD, comments on a phase 2 study examining the use of chemotherapy with durvalumab in patients with pleural mesothelioma.
Claire Verschraegen, MD,...
06/30/2020
Oncology
Researchers Demonstrate Promising Efficacy of Lorlatinib in Patients With ALK+ NSCLC
Videos
Researchers Demonstrate Promising Efficacy of Lorlatinib in Patients With ALK+ NSCLC
06/10/2020
David Carbone, MD, PhD, offers his perspective on 2 clinical trials that evaluated the use of lorlatinib in patients with ALK-positive NSCLC.
David Carbone, MD, PhD, offers his perspective on 2 clinical trials that evaluated the use of lorlatinib in patients with ALK-positive NSCLC.
David Carbone, MD, PhD, offers...
06/10/2020
Oncology
Alectinib Extends Survival in Treatment-Naïve Patients With ALK+ NSCLC
Videos
Alectinib Extends Survival in Treatment-Naïve Patients With ALK+ NSCLC
06/04/2020
Yasir Elamin, MD, discusses the findings of a study comparing alectinib with crizotinib in treatment-naïve patients with ALK-positive NSCLC.
Yasir Elamin, MD, discusses the findings of a study comparing alectinib with crizotinib in treatment-naïve patients with ALK-positive NSCLC.
Yasir Elamin, MD, discusses the...
06/04/2020
Oncology
Combining Immuno-Oncology and Standard Chemo in the Treatment of NSCLC
Videos
Combining Immuno-Oncology and Standard Chemo in the Treatment of NSCLC
06/03/2020
Solange Peters, MD, PhD, provides a summation of the Keynote-189, CheckMate 9LA, and CheckMate 227 clinical trials, and what the findings of these studies mean for the treatment of patients with NSCLC.
Solange Peters, MD, PhD, provides a summation of the Keynote-189, CheckMate 9LA, and CheckMate 227 clinical trials, and what the findings of these studies mean for the treatment of patients with NSCLC.
Solange Peters, MD, PhD,...
06/03/2020
Oncology
NGS of Cell-Free Plasma DNA Shows Value in Management of Patients With ALK+ NSCLC
Videos
NGS of Cell-Free Plasma DNA Shows Value in Management of Patients With ALK+ NSCLC
06/02/2020
David Carbone, MD, PhD, talks about the usefulness of NGS for cell-free plasma DNA in patients with ALK-positive NSCLC.
David Carbone, MD, PhD, talks about the usefulness of NGS for cell-free plasma DNA in patients with ALK-positive NSCLC.
David Carbone, MD, PhD, talks...
06/02/2020
Oncology
Recent Advancements in the Treatment of HER2+ NSCLC
Videos
Recent Advancements in the Treatment of HER2+ NSCLC
06/01/2020
Solange Peters, MD, PhD, discusses the DESTINY trial and recent advancements made in the exploration of treatment options for patients with HER2-positive NSCLC.
Solange Peters, MD, PhD, discusses the DESTINY trial and recent advancements made in the exploration of treatment options for patients with HER2-positive NSCLC.
Solange Peters, MD, PhD,...
06/01/2020
Oncology
Videos
Anti–PD-L1 Therapy Not Recommended for Patients With NSCLC, Active Brain Metastases
06/01/2020
David Carbone, MD, PhD, comments on a study evaluating the efficacy of anti–PD1/PD-L1 monotherapy for patients with NSCLC and active brain metastases.
David Carbone, MD, PhD, comments on a study evaluating the efficacy of anti–PD1/PD-L1 monotherapy for patients with NSCLC and active brain metastases.
David Carbone, MD, PhD, comments...
06/01/2020
Oncology
Lorlatinib Shows Promise in Real-World Study of Patients With ALK+ NSCLC
Videos
Lorlatinib Shows Promise in Real-World Study of Patients With ALK+ NSCLC
06/01/2020
Yasir Elamin, MD, talks about how a study examining the real-world use of lorlatinib for ALK-positive NSCLC supports previously reported phase 2 trial data about this drug.
Yasir Elamin, MD, talks about how a study examining the real-world use of lorlatinib for ALK-positive NSCLC supports previously reported phase 2 trial data about this drug.
Yasir Elamin, MD, talks about...
06/01/2020
Oncology
News
LCT With Brigatinib Shows Efficacy in TKI-Naïve Patients With ALK-Positive NSCLC
05/31/2020
Study findings posit LCT with brigatinib as a safe and effective treatment option for patients with ALK-rearranged advanced NSCLC, regardless of the number of metastatic sites.
Study findings posit LCT with brigatinib as a safe and effective treatment option for patients with ALK-rearranged advanced NSCLC, regardless of the number of metastatic sites.
Study findings posit LCT with...
05/31/2020
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

September 18 ⁠–⁠ September 20
September 20 ⁠–⁠ September 22
September 21 ⁠–⁠ September 22
AMP Europe
September 30 ⁠–⁠ October 2
October 1 ⁠–⁠ October 2
SAWC Fall
October 2 ⁠–⁠ October 5
October 5 ⁠–⁠ October 6
SMASH
October 14 ⁠–⁠ October 16
Lymphoma, Leukemia, and Myeloma
October 16 ⁠–⁠ October 19
October 19 ⁠–⁠ October 20
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use